Browse Studies — Arctuva

Phase 2

A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults with Pulmonary Hypertension …

Pulmonary Hypertension Due to Lung Diseases and Hypoxia

Estimated

~$10 – $8,750

OrphAI TherapeuticsNCT05798923

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interst…

Pulmonary Hypertension Due to Lung Diseases and HypoxiaPulmonary HypertensionInterstitial Lung Disease

Estimated

~$10 – $1,050

United TherapeuticsNCT06388421

Observational

Ventilator Pressure and Optimization of Compliance and Hemodynamics: VPOCH Trial

In preterm infants \< 34 weeks' gestation at birth receiving respiratory support with invasive positive pressure ventilation, the positive end-expiratory press…

Bronchopulmonary DysplasiaPulmonary Hypertension Due to Lung Diseases and HypoxiaExtreme Prematurity+2 more

Estimated

~$10 – $6,250

University of Alabama at BirminghamNCT06512935

Pulmonary Hypertension Biorepository and Registry

Establish a pulmonary hypertension registry and biorepository to lead towards a further understanding of the disease.

Pulmonary HypertensionPulmonary Arterial HypertensionPulmonary Hypertension Due to Left Heart Disease+6 more

Estimated

~$10 – $750

University of Kansas Medical CenterNCT04808596